Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: Relationship with left ventricular perfusion and contractile function

Journal of Computer Assisted Tomography

Volumn 30, Issue 3, 2006, Pages 412-420

  Soler, Rafaela ^a,b   Rodríguez, Esther ^a,b   Monserrat, Lorenzo ^a,b   Méndez, Cristina ^a   Martínez, Covadonga ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Spanish Cardiovascular Network ^*  (Spain)

Author keywords

FOV = field of view; MCH = hypertrophic cardiomyopathy

Indexed keywords

DEFECTS; PATIENT MONITORING; RISK ASSESSMENT;

AT RESTS; FIELD OF VIEWS; FOV = FIELD OF VIEW; GRADIENT ECHO SEQUENCES; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR; MCH = HYPERTROPHIC CARDIOMYOPATHY; MULTIPHASES; PERFUSION DEFECTS; WALL THICKNESS;

MAGNETIC RESONANCE IMAGING;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PERFUSION; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PRIORITY JOURNAL;

EID: 33745288752     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-200605000-00011     Document Type: Article

References (30)

1. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). J Am Coll Cardiol. 2003;42:410-418.
2. McKenna WJ, Monserrat L. Identification and treatment of patients with hypertrophic cardiomyopathy at risk of sudden death. Rev Esp Cardiol. 2000;53:123-130.
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004; 363:1881-1891.
4. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Eng J Med. 2000;342:1778-1785.
5. Yamada M, Elliott PM, Kaski JC, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. Eur Heart J. 1998;19:500-507.
6. Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17:879-886.
7. Crowley JJ, Dardas PS, Harcombe AA, et al. Transthoracic Doppler echocardiographic analysis of phasic coronary blood flow velocity in hypertrophic cardiomyopathy. Heart. 1997;77:558-563.
8. Kawada N, Sakuma H, Yamakado T, et al. Hypertrophic cardiomyopathy: MR measurement of coronary blood flow and vasodilator flow reserve in patients and healthy subjects. Radiology. 1999;211:129-135.
9. Sipola P, Lauerma K, Husso-Saastamoinen M, et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology. 2003;26:129-137.
10. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-2164.
11. Bogaert J, Goldstein M, Tannouri F, et al. Original report. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR. 2003;180:981-985.
12. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
13. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-2264.
14. Amano Y, Takayama M, Takahama K, et al. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. J Magn Reson Imaging. 2004;20:595-600.
15. Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22:155-1161.
16. Sardanelli F, Molinari G, Petillo A, et al. MRI in hypertrophic cardiomyopathy: a morphofunctional study. J Comput Assist Tomogr. 1993;17:862-872.
17. Soler R, Rodríguez E, Marini M. Left ventricular mass in hypertrophic cardiomyopathy: assessment by three-dimensional and geometric methods. J Comput Assist Tomogr. 1999;23:577-582.
18. Reichek N. MRI myocardial tagging. J Magn Reson Imaging. 1999;10:609-616.
19. Edelman RR. Contrast-enhanced MR imaging of the heart: overview of the literature. Radiology. 2004;232:568-653.
20. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation. 2002;106:2322-2327.
21. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
22. Moon JC, Lorenz CH, Francis JM, et al. Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility. Radiology. 2002;223:789-797.
23. Shirani J, Pick R, Roberts WC, et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44.
24. Ino T, Nishimoto K, Okubo M, et al. Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. Am J Cardiol. 1997;79:1137-1141.
25. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1333-1340.
26. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58-60.
27. Perrone-Filardi P, Bacharach SL, Dilsizian V, et al. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol. 1993;7:199-204.
28. Basso C, Thiene G, Corrado D, et al. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol. 2000;31:988-998.
29. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557.
30. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027-1035.